Other mutations in profilin 1 that hinder profilin’s interactions with actin or poly-L-proline (PLP) containing proteins demonstrated enhanced tumorigenic properties indicating the significance of serine phosphorylation of profilin in cancer progression and the potential in making pS137 a chemotherapeutic target to curb breast cancer. This evidence concerns the gene PFN1 and breast carcinoma.